Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00195702 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

A Phase 3 study, sponsored by Abbott.

Completed
Registry status
Phase 3
Development phase
619
Enrollment target

NCT00195702 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 619 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00195702, a Phase 3 study, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 3
Development phase
619 participants
Enrollment target

Study Summary

The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.

Interventions

  • DRUG Placebo
  • BIOLOGICAL Adalimumab

Trial Details

FieldValue
Enrollment Target 619 participants
Start Date 2000-02
Est. Completion 2010-08
Phase Phase 3

Sponsor

Abbott

181 total trials

What the Registry Record Tells You About NCT00195702

The ClinicalTrials.gov registry entry for NCT00195702 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 619 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00195702 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00195702 about?

NCT00195702 is a clinical study titled "Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.". The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension ph...

What is the current status of trial NCT00195702?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2000-02. Estimated completion is 2010-08.

What interventions are being tested in trial NCT00195702?

The interventions under investigation include: Placebo (DRUG), Adalimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00195702?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.